<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Gibson Hunt | Activity</title>
	<link>https://www.catswannabecats.com/members/legsneeze5/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/legsneeze5/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Gibson Hunt.</description>
	<lastBuildDate>Wed, 01 Jul 2026 18:37:05 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">0f288446a0eb546d8f909b9024d63118</guid>
				<title>Gibson Hunt posted an update: Using a novel mathematical model, we show that NTBC could [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23357/</link>
				<pubDate>Sun, 08 Jun 2025 08:59:01 -0400</pubDate>

									<content:encoded><![CDATA[<p>Using a novel mathematical model, we show that NTBC could reduce the transmission of African trypanosomiasis in sub-Saharan Africa, thus accelerating current disease elimination programmes.Coronavirus disease 2019 (COVID-19) is a new disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. China reported the first&hellip;<span class="activity-read-more" id="activity-read-more-23357"><a href="https://www.catswannabecats.com/activity/p/23357/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d7d2ad65980c692b60d291a07062e41b</guid>
				<title>Gibson Hunt posted an update: Pre-procedural PVC burden did not differ between patients [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/11455/</link>
				<pubDate>Sun, 01 Jun 2025 06:22:01 -0400</pubDate>

									<content:encoded><![CDATA[<p>Pre-procedural PVC burden did not differ between patients with sustained ablation success and recurrence during follow-up (median 21%vs. 22%, p=.76). When assessed in pre-ablation PVC-burden groups of ≤5%, 6-15%, 16-30%, and ≥31%, sustained ablation success was achieved in 67%, 75%, 71%, and 72%, respectively, with no significant difference (p=&hellip;<span class="activity-read-more" id="activity-read-more-11455"><a href="https://www.catswannabecats.com/activity/p/11455/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">2dcc419ca7a4c4bc0ff5e69bba5f6682</guid>
				<title>Gibson Hunt became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/10851/</link>
				<pubDate>Sun, 01 Jun 2025 03:12:30 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>